Predictors of Residual Nodal Disease After Positive Sentinel Lymph Node Biopsy: A Retrospective Cohort Study of Axillary De-escalation in Breast Cancer White Axilla in Breast Cancer
Abstract
Background: The management of the axilla following a positive sentinel lymph node biopsy (SLNB) in breast cancer remains a nuanced clinical challenge. A significant proportion of these patients will have no additional nodal disease identified on completion axillary lymph node dissection (ALND)—a phenomenon colloquially referred to in some institutions as the "white axilla" (i.e., no residual nodal disease). This phenomenon questions the universal application of ALND, a procedure associated with considerable morbidity. This study aims to quantify the incidence of no residual nodal disease after positive SLNB and to identify the clinicopathological factors predictive of additional nodal metastases to refine surgical decision-making.
Methods: A single-center, retrospective cohort study was conducted on patients with invasive breast cancer and a positive SLNB who had undergone completion ALND at Rotherham Foundation Trust, UK, between 2010 and 2023. Clinicopathological variables including tumor size, grade, receptor status, lymphovascular invasion (LVI), and extracapsular extension (ECE) were analyzed. The predictive performance of the Memorial Sloan Kettering (MSK) nomogram was also evaluated. Multivariable logistic regression was performed, with two separate models for clinicopathological variables and nomogram scores to avoid collinearity. The primary dependent outcome variable for multivariable logistic regression was the presence versus absence of residual nodal metastasis on completion axillary lymph node dissection.
Results: Among 160 eligible patients (after excluding 17 patients due to incomplete histopathology records, prior ipsilateral axillary surgery, or presentation with cN+ disease), 96 (60.0%) exhibited no further nodal involvement. This group was characterized by significantly lower Nottingham Prognostic Index (NPI) scores (mean 4.8 vs. 5.06, P = .04), smaller median primary tumor size (33.7 mm vs. 39.1 mm, P = .04), and a lower incidence of ECE (31.3% vs. 53.1%, P = .006). Multivariable logistic regression identified tumor size >35 mm (adjusted OR 2.11, 95% CI 1.08–4.12, P = .03), presence of ECE (adjusted OR 2.63, 95% CI 1.36–5.09, P = .004), and HER2-negative status (adjusted OR 3.87, 95% CI 1.23–12.21, P = .02) as independent predictors of non-sentinel node metastasis. When the MSK nomogram score was analyzed as a continuous variable, it demonstrated a good discriminatory ability (AUC 0.81, 95% CI 0.74–0.88).
Conclusion: The high proportion of patients without residual nodal disease in this cohort suggests that completion ALND may be unnecessary for many patients with a positive SLNB. The identified predictive factors may help guide a more selective, personalized approach to axillary management. These findings should be interpreted with awareness of the institutional practice pattern during this era, recognizing that evaluating Z0011 adherence was not a goal of this study. Prospective validation is warranted.
References
Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365-83. doi: 10.1200/JCO.2013.54.1177
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881-8. doi: 10.1016/S1470-2045(07)70278-4
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918-26. doi: 10.1001/jama.2017.11470
Yi M, Meric-Bernstam F, Ross MI, Akins JS, Hwang RF, Lucci A, et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?. Cancer. 2008;113(1):30-7. doi: 10.1002/cncr.23514
Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 1998;227(5):645-53. doi: 10.1097/00000658-199805000-00005
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-75. doi: 10.1001/jama.2011.90
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297-305. doi: 10.1016/S1470-2045(13)70035-4
Houvenaeghel G, Classe JM, Garbay JR, Giard S, Cohen M, Faure C, et al. Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: a French sentinel node multicenter cohort study. Breast. 2014;23(5):561-6. doi: 10.1016/j.breast.2014.04.004
Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3(4):549-55. doi: 10.1001/jamaoncol.2016.4163
Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27(18):2946-53. doi: 10.1200/JCO.2008.19.5750
Memorial Sloan Kettering Cancer Center. Breast cancer nomogram: breast additional non-SLN metastases [Internet]. New York: Memorial Sloan Kettering Cancer Center; 2026 Oct 4. [cited 2026 Oct 4]. Available from: https://www.mskcc.org/nomograms/breast
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2024.
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072-8. doi: 10.1200/JCO.2015.64.0094
Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast. 2012;21(5):678-81. doi: 10.1016/j.breast.2012.06.013
Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307-16. doi: 10.1056/NEJMoa1415340
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303-10. doi: 10.1016/S1470-2045(14)70460-7
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700-12. doi: 10.1093/annonc/mdx308
Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, et al. A prognostic index in primary breast cancer. Br J Cancer. 1982;45(3):361-6. doi: 10.1038/bjc.1982.62
Van Zee KJ, Manasseh DME, Bevilacqua JLB, Boolbol SK, Fey JV, Tan LK, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140-51. doi: 10.1245/ASO.2003.03.015
Degnim AC, Griffith KA, Sabel MS, Hayes DF, Cimmino VM, Diehl KM, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer. 2003;98(11):2307-15. doi: 10.1002/cncr.11803
Authors
Copyright (c) 2026 Rami Oweis, Dominic Luttrell, Shadan Jan, Alexander Marinov, Bertha In't Hout, Lisa Caldon, Tahir Masudi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.